Article in Artificial intelligence in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Matthew EngelhardDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, United States of America; Duke AI Health, United States of America. Electronic address: m.engelhard@duke.edu.
Daniel WojdylaDuke Clinical Research Institute, United States of America.
Haoyuan WangDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, United States of America.
Michael PencinaDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, United States of America; Duke AI Health, United States of America; Duke Clinical Research Institute, United States of America.
Ricardo HenaoDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, United States of America; Duke AI Health, United States of America; Duke Clinical Research Institute, United States of America.
Funding
VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0M
Genetic underpinnings of cardiorenal risk in Africans and African AmericansR01HL136666 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI IRVIN, MARGUERITE R, LANGE, LESLIE A · 2017 to 2020
$2.6M
Data HarmonizationR61NS120246 · NINDS · DUKE UNIVERSITY · PI PENCINA, MICHAEL J · 2020 to 2022
$2.0M
Data HarmonizationR33NS120246 · NINDS · DUKE UNIVERSITY · PI PENCINA, MICHAEL J · 2023 to 2024
$1.3M
Machine Learning Methods to Develop and Deploy Real-Time Risk Surveillance for Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder from the Electronic Health RecordK01MH127309 · NIMH · DUKE UNIVERSITY · PI Matthew Morrow Engelhard · 2022 to 2026
$842k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDYN01HC095166 · HC · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI TRACY, RUSSELL P · 1999 to 2001
$758k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095162 · HC · JOHNS HOPKINS UNIVERSITY · PI SZKLO, MOYSES A · 1999 to 2000
$694k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095161 · HC · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEA, STEVEN · 1999 to 2001
$642k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095165 · HC · WAKE FOREST UNIVERSITY · PI BURKE, GREGORY L · 1999 to 2001
$616k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTERN01HC095160 · HC · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SAAD, MOHAMMED F · 1999 to 2001
$592k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY-FIELD CENTERN01HC095164 · HC · NORTHWESTERN UNIVERSITY · PI LIU, KIANG JOHN · 1999 to 2001
A recent analysis of common stroke risk prediction models showed that performance differs between Black and White subgroups, and that applying standard machine learning methods does not reduce these disparities. There have been calls in the clinical literature to correct such disparities by removing race as a predictor (i.e., race-free models). Alternatively, a variety of machine learning methods have been proposed to constrain differences in model predictions between racial groups. In this work, we compare these approaches for equitable stroke risk prediction. We begin by proposing a discrete-time, neural network-based time-to-event model that incorporates a parity constraint designed to make predictions more similar between groups. Using harmonized data from Framingham Offspring, MESA, and ARIC studies, we develop both parity-constrained and unconstrained stroke risk prediction models, then compare their performance with race-free models in a held-out test set and a secondary validation set (REGARDS). Our evaluation includes both intra-group and inter-group performance metrics for right-censored time to event outcomes. Results illustrate a fundamental trade-off in which parity-constrained models must sacrifice intra-group calibration to improve inter-group discrimination performance, while the race-free models strike a balance between the two. Consequently, the choice of model must depend on the potential benefits and harms associated with the intended clinical use. All models as well as code implementing our approach are available in a public repository. More broadly, these results provide a roadmap for development of equitable clinical risk prediction models and illustrate both merits and limitations of a race-free approach.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Exploring trade-offs in equitable stroke risk prediction with parity-constrained and race-free models. · full record | OpenQuestion